Literature DB >> 32043

Comparison of disposition and effect of timolol and propranolol on exercise tachycardia.

T Ishizaki, K Tawara.   

Abstract

The kinetic disposition and beta-adrenergic blocking action in relation to plasma level of a single oral dose of either timolol or propranolol has been compared in healthy male volunteers. The disposition profiles clearly disclosed different properties of the two drugs, although their half-lives were similar. The available fraction of timolol in the systemic circulation was estimated to be approximately 60% of the dose, and 17.4% was exereted unchanged in urine. The logarithm of plasma concentration showed a significant correlation with the beta-blocking activity assessed by an exercise test. The mean potency ratios of timolol to propranolol as an antagonist of chronotropic effects on exercise tachycardia were 11 to 17 and 3.6 to 5.5 in dose- and concentration-effect relationships, respectively. The absolute reduction of exercise heart rate gave the best coefficient of all measures of beta-blockade. When drug action was measured as beta-blockade assessed by a given response to exercise tachycardia, the effect declined linearly with time, even though plasma levels fell exponentially. This results suggest that the pharmacokinetic t1/2 is much shorter than the pharmacological t1/2.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 32043     DOI: 10.1007/bf00560252

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man.

Authors:  R Gugler; W Höbel; G Bodem; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

3.  Physiological disposition and metabolism of timolol in man and laboratory animals.

Authors:  D J Tocco; A E Duncan; F A Delauna; H B Hucker; V F Gruber; W J Vandenheuvel
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

4.  Intrinsic heart rate on exercise and the measurement of beta-adrenoceptor blockade.

Authors:  S G Carruthers; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

5.  Acebultolol: basis for the prediction of effect on exercise tolerance.

Authors:  P Biron; G Tremblay
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

6.  Relationship between blood level of atenolol and pharmacologic effect.

Authors:  A Amery; J F De Plaen; P Lijnen; J McAinsh; T Reybrouck
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

7.  Propranolol and cardiac surgery.

Authors:  J F Viljoen; F G Estafanous; G A Kellner
Journal:  J Thorac Cardiovasc Surg       Date:  1972-11       Impact factor: 5.209

8.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

9.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

10.  Electron-capture GLC determination of timolol in human plasma and urine.

Authors:  D J Tocco; F A deLuna; A E Duncan
Journal:  J Pharm Sci       Date:  1975-11       Impact factor: 3.534

View more
  5 in total

1.  The effect of propranolol on exercise induced tachycardia is determined by plasma concentration and the density of adrenergic receptors on leukocytes.

Authors:  K Tawara; E Steiner; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

3.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.

Authors:  T Ishizaki; Y Oyama; T Suganuma; T Sasaki; H Nakaya; T Shibuya; T Sato
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.